USA
Analytical Standards
Controlled Research Environment
Research Product
CJC – 1295 / Ipamorelin
1. Product Overview
CJC-1295 / Ipamorelin is a research peptide blend combining two extensively studied growth hormone regulatory peptides in a standardized lyophilized formulation. The blend has attracted significant scientific interest in research involving growth hormone signaling, peptide receptor interactions, endocrine function, metabolic regulation, and body composition studies. Each component is investigated for its unique interaction with growth hormone-related biological pathways, making the combination a widely recognized subject of research.
Manufactured in a controlled research environment, the formulation undergoes analytical testing to verify identity, purity, and consistency prior to release. The product is supplied as a lyophilized research peptide blend intended exclusively for laboratory and scientific research applications.
2. Specifications
| Product Name | CJC – 1295 / Ipamorelin | Testing Method | HPLC |
|---|---|---|---|
| Synonym | PF-02 peptide profile | Storage Condition | 2-8C |
| Format | Lyophilized Powder | Shelf Life | 24 Months |
| Content | 7 mg per vial | Manufacturing Standard | GMP Standard Research Environment |
| Purity | >=99% HPLC | Country of Origin | USA |
| Appearance | White to Off White Lyophilized Powder | Intended Use | Research Use Only |
3. Research Summary
CJC-1295 / Ipamorelin is a research peptide blend combining a growth hormone-releasing hormone (GHRH) analogue with a growth hormone secretagogue receptor (GHS-R) agonist. This formulation has attracted scientific interest in studies involving endocrine signaling, peptide receptor interactions, growth hormone regulatory pathways, metabolic processes, and neuroendocrine communication mechanisms.
CJC-1295 has been extensively studied for its interaction with growth hormone-releasing hormone pathways, while Ipamorelin has been investigated for its selective interaction with growth hormone secretagogue receptors. Ongoing laboratory research continues to explore the combined activity of these peptides in endocrine, metabolic, and peptide signaling models.
4. Scientific References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
- Jette L, Leger R, Thibaudeau K, et al. Human growth hormone releasing factor analogue (CJC-1295) studies in endocrine research. Growth Hormone & IGF Research. 2005;15(6):367-377.
- Deghenghi R, Cananzi MM, Torsello A, et al. Growth hormone-releasing activity of Ipamorelin. European Journal of Endocrinology. 1998;139(1):89-95.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, a new growth hormone secretagogue with receptor selectivity. European Journal of Endocrinology. 1998;139(5):552-561.
- Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML. Growth hormone-releasing hormone and growth hormone secretagogues in research and clinical investigation. Endocrine Reviews. 1997;18(5):621-645.
Disclaimer: This product is intended strictly for research use only. It is not intended for human consumption, clinical application, diagnostic procedures, therapeutic use, veterinary use, or household use. The information provided is for scientific and educational reference purposes only and should not be interpreted as medical advice, treatment guidance, or usage instructions. This product should be handled only by qualified professionals trained in laboratory practices. Purchasers and end users are solely responsible for ensuring compliance with all applicable laws, regulations, and institutional requirements governing the purchase, storage, handling, and use of research materials.
